Journal Mobile Options
Table of Contents
Vol. 19, No. 6, 1998
Issue release date: November–December
Section title: 20th Anniversary Meeting on SCC Antigen · Proceedings
Tumor Biol 1998;19:505–516
(DOI:10.1159/000030044)

The Clinical Value of Squamous Cell Carcinoma Antigen in Cancer of the Uterine Cervix

de Bruijn H.W.A. · Duk J.M. · van der Zee A.G.J. · Pras E. · Willemse P.H.B. · Boonstra H. · Hollema H. · Mourits M.J.E. · de Vries E.G.E. · Aalders J.G.
Departments of Obstetrics and Gynecology, Radiotherapy, Medical Oncology, and Pathology, University Hospital, Groningen, The Netherlands

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of 20th Anniversary Meeting on SCC Antigen · Proceedings

Published online: 11/16/1998

Number of Print Pages: 12
Number of Figures: 5
Number of Tables: 4

ISSN: 1010-4283 (Print)
eISSN: 1423-0380 (Online)

For additional information: http://www.karger.com/TBI

Abstract

A review is given of the clinical use and interpretation of serum tumor marker levels during the treatment of patients with cancer of the uterine cervix. Pretreatment serum squamous cell carcinoma (SCC) antigen provides a new prognostic factor in early stage squamous cell carcinoma of the uterine cervix. Elevated serum values of SCC antigen at the time of diagnosis of stage IB and IIA cervical cancer indicate a 3 × increased risk of tumor recurrence, independent of tumor diameter, grade or the presence of lymph node metastases. High pretreatment SCC antigen levels could therefore be used to select ‘high-risk’ patients for adjuvant therapy. Measurement of the serum SCC antigen levels provides a means of monitoring the effect of therapy. During the postoperative follow-up of patients with localized cancer of the uterine cervix the measurement of SCC antigen can lead to the early detection of recurrent disease when curative therapy is still an option. The profile of serum SCC antigen parallels the response to radiotherapy and provides a way of evaluating the effectiveness of chemotherapy. Serial measurements after surgery and during radio- and chemotherapy demonstrate that SCC antigen is a more sensitive marker for recognizing tumor progression or recurrence than CYFRA-21.1, TPS or CEA. When following up patients with a pure adenocarcinoma of the cervix measurements of serum CA 125 and CEA are preferred over SCC antigen measurements.


  

Author Contacts

Henk W.A. de Bruijn, PhD
Lab. Obstetrics and Gynaecology, University Hospital Groningen
Hanzeplein 1, Room Y 42.38, PO Box 30.001
NL–9700 RB Groningen (The Netherlands)
Tel. +31 50 3616161/3613014, Fax +31 50 3611694

  

Article Information

Number of Print Pages : 12
Number of Figures : 5, Number of Tables : 4, Number of References : 66

  

Publication Details

Tumor Biology (From Basic Science to Clinical Application)
Founded 1980 as ‘Oncodevelopmental Biology and Medicine’ by the ISOBM, continued 1984–1986 as ‘Tumour Biology’
The Journal of the International Society for Oncodevelopmental Biology and Medicine (ISOBM)

Vol. 19, No. 6, Year 1998 (Cover Date: November-December)

Journal Editor: S. von Kleist, Freiburg i.Br.
ISSN: 1010–4283 (print), 1423–0380 (Online)

For additional information: http://www.karger.com/journals/tbi


Article / Publication Details

First-Page Preview
Abstract of 20th Anniversary Meeting on SCC Antigen · Proceedings

Published online: 11/16/1998

Number of Print Pages: 12
Number of Figures: 5
Number of Tables: 4

ISSN: 1010-4283 (Print)
eISSN: 1423-0380 (Online)

For additional information: http://www.karger.com/TBI


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.